Maurice was pacing the length of his monitor, occasionally tossing banana peels at a chart of RCKT’s price action, muttering about the beautiful irony of good news triggering a sell-off.
Here’s a thing that drives me absolutely bananas: a company gets FDA approval for a gene therapy that could change lives, and the stock craters 8.9%. Not because the therapy is bad. Not because the company botched the approval. But because the market is having what I can only describe as a existential crisis about what good news even means anymore.
Welcome to Rocket Pharmaceuticals (RCKT), where the most important clinical victory in the company’s 25-year history just became a reason to sell first and ask questions later.
Let me back up. Three weeks ago—on March 27, 2026—Rocket announced FDA Accelerated Approval for KRESLADI, a gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I) in children. This is not a small thing. LAD-I is a genetic disorder where the immune system basically forgets how to work. Kids with this disease get life-threatening infections. Their parents watch them slowly deteriorate. There is no cure. There is barely a treatment. And now there’s KRESLADI.
The stock response? Down 8.9%. Then down another 8.9%. Then down another few percentage points because, well, momentum works both ways and apparently nobody told the market that approvals are good.
I’ve been thinking about this for days, and I think I finally understand what happened. The market was expecting Rocket to be a different company after this approval. It expected confidence. Celebration. A management team standing on stage talking about commercial rollout and peak sales projections. Instead, what it got was… nuance. Reality. The understanding that even though this is transformative from a medical perspective, it’s transformative in a market measured in maybe 100-200 kids a year in the United States. That’s not a blockbuster. That’s a rare disease therapy, which means small but dedicated patient populations, high price points, and margins that look beautiful until you realize you’re talking about maybe $50-100 million in peak annual sales. For a biotech. That spent years burning cash to get here.
But here’s where Maurice starts to get interested. Because the market, in its infinite wisdom, has created what looks like a genuine opportunity—if you’re willing to think past the next three days of trading.
The Current Situation: A Stock Trading at Divorce Settlement Prices
Rocket is trading at $3.64 right now. The 52-week high is $8.26. The recommendation we’re looking at suggests an entry around $4.97 with a target of $9.50. Those numbers were written when the stock was higher and presumably less panicked. Today, at $3.64, we’re actually below where the recommendation suggested entering.
Think of it like a banana stand owner who’s built the perfect stand, trained all the employees, got his health permit approved with flying colors—and then watched customers run past him because they’re worried about whether bananas will still be popular next week. The stand is real. The bananas are real. The business is real. The fear, however, is also real, and fear moves markets faster than fact.
The fundamentals tell a story that the stock price seems determined to ignore. Rocket has minimal debt ($8.97 debt-to-equity ratio—actually better than the research data I’m seeing, though that data looks slightly outdated). The company burns cash, yes, but that’s what biotech companies do when they’re funding phase 2 trials and commercial launch preparation. The beta is 0.574, which means this stock moves dramatically less than the broader market—that’s actually protective on the downside, even if it feels like a prison when everyone else is rallying.
The analyst consensus target is $8.48. That’s not some pie-in-the-sky fantasy. That’s Wall Street’s analytical framework suggesting we’re roughly 130% undervalued from here. Eleven analysts covering this stock. That’s not some forgotten penny stock; this is a company people are paying attention to.
So why has the market decided it hates Rocket? I think it’s because gene therapy is still treated like voodoo by most investors. There’s a 2023 narrative about gene therapy overhyping that’s calcified into people’s brains. “Gene therapy always fails.” “Gene therapy promises never materialize.” “Gene therapy companies burn billions for a single patient.” These narratives sound wise and cautious. They’re also increasingly outdated.
The Pipeline: This Isn’t Just a One-Hit Wonder
Here’s what I find genuinely compelling about Rocket’s situation: KRESLADI is important, but it’s not the whole story. The company has a pipeline that looks like a fruit basket with multiple varieties of potential.
The LAD-I program (KRESLADI, just approved) targets a small population, but it’s a proof-of-concept victory. It shows that Rocket can execute. It shows that the FDA will approve their approach. That matters immensely for the next phase of programs.
Then there’s RP-A501, targeting Danon disease (a rare cardiomyopathy). This is in phase 2. The cardiac space is massive—cardiomyopathy affects millions. Even a therapy targeting a rare genetic subset could eventually reach a meaningful market size. Phase 2 success here would be genuinely transformational for the stock valuation.
RP-A601 (PKP2-Associated Arrhythmogenic Cardiomyopathy) is in phase 1. RP-L102 (Fanconi Anemia) is being studied. The company is building a genuine portfolio, not a one-trick pony.
This is like a farmer who just harvested his first crop successfully, proved he knows what he’s doing, and now is preparing to scale up with multiple crop varieties. The market is panicking about the first harvest’s modest size. It’s ignoring the land, the seeds, and the demonstrated capability.
The Bear Case: And Why It’s Not Nothing
I’d be doing you a disservice if I didn’t acknowledge the real risks here, because they exist and they’re non-trivial.
First: cash burn. Rocket’s free cash flow is negative $104 million annually. The company has a $395 million market cap. Do the math. At current burn rates, they have roughly four years of cash. That timeline assumes no additional funding, which is unrealistic, but it also assumes things go according to plan, which is overly optimistic for biotech. Phase 2 trials can expand. Regulatory discussions can drag. Commercial rollout can cost more than projected. Four years feels comfortable until it suddenly doesn’t.
Second: rare disease markets are… rare. There’s no volume. KRESLADI might achieve peak sales of $80 million annually if everything goes perfectly. That’s great for a rare disease. It’s not a platform. It’s not a franchise. It’s a single drug for a single disease affecting a few hundred people worldwide. The next programs need to work, and they need to work in bigger populations, or Rocket remains a curiosity rather than a company.
Third: gene therapy is still unproven at scale in the commercial market. Novartis’ Zolgensma was approved in 2019 for SMA. It works. But the logistics are nightmare-inducing. You’re transporting products that need to stay cold, you’re treating a limited number of patients, and you’re competing against standard of care plus time—the clock starts the moment these kids are born. Gene therapy in cardiac diseases is even less proven. There are real efficacy questions, durability questions, and manufacturing scalability questions that nobody has fully answered yet.
Fourth: short interest. The short ratio is 4.64 days. That means roughly 4.64 days of trading volume would be required to cover all short positions. That’s elevated. That’s the market saying “we think this fails.” Short squeezes happen, but relying on one is not a strategy—it’s gambling.
So the bear case is real: underfunded biotech with unproven therapies in limited markets, burning cash, with most of its value depending on phase 2 and 3 trial success. That’s not paranoia. That’s accurate risk assessment.
The Bull Case: Why Contrarian Thinking Might Actually Work Here
But here’s where I part ways with the market’s current consensus panic.
Gene therapy adoption is accelerating. The regulatory pathway is becoming clearer. The FDA just accelerated approved KRESLADI. They’re not doing that for vaporware. Manufacturing is improving. The cost structure is becoming more favorable. Wedbush Securities (legitimate shop, by the way) came out in early March saying Rocket is “significantly undervalued” as the cardiac pipeline advances. That wasn’t written before the approval—it was written knowing exactly what the company was doing.
The market is treating Rocket like it’s 2018 and gene therapy is theoretical. It’s 2026. It’s approved. It’s real. The second and third derivatives of this company—what happens if the cardiac programs work, if they partner with bigger pharma, if they get acquired—those are where the real value sits. And they’re currently being priced like they have a 5% probability of success.
Here’s my take: the market has created a banana stand where the stand is actually profitable, but everyone’s worried bananas will go out of style. They won’t. In fact, the market for rare genetic diseases is only getting larger as genomic medicine accelerates.
The entry point Foxy suggested was $4.97. We’re at $3.64. That’s roughly a 27% discount to the suggested entry. Either Foxy’s analysis was wrong, or the market has overcorrected, or both. I’m inclined to think it’s the latter—that Foxy’s confidence (8/10) was reasonable, and the post-approval panic has created an even better entry point than originally identified.
The target of $9.50 implies roughly 161% upside from here. That’s not frivolous. That’s based on analyst consensus suggesting $8.48. That’s based on actual programs with actual FDA approval moving forward. That’s based on a company that, despite the hysteria, has actually de-risked meaningfully over the past few weeks.
The Three-Year Thesis
I’m not recommending Rocket as a day trade or even a one-year hold. I’m suggesting it as a three-to-five-year thesis with genuine catalysts and genuine risks.
Year one: KRESLADI commercial rollout. The company shows it can execute. Analysts begin modeling revenue. The narrative shifts from “unproven biotech” to “early commercial gene therapy player.” Stock rerates to $5-6 on increased investor confidence.
Year two: Phase 2 cardiac data begins emerging. If positive, the story changes dramatically. Suddenly Rocket isn’t a rare disease company—it’s a rare disease company with exposure to a massive cardiac market. Stock moves to $7-9.
Year three: Partnerships or acquisition rumors emerge. Maybe Wedbush was right about the undervaluation and a bigger pharma company starts sniffing around. Maybe the company partners to fund later-stage trials. Maybe they’re just executing so well that everyone’s realized the initial panic was absurd. Stock moves toward $9.50-12.
None of this is guaranteed. Rockets explode sometimes. That’s why the risk level is medium, not low. But the asymmetry is there: you’re risking $3.64 to make $9.50. That’s a 2.6:1 payoff ratio for a medium-risk situation. That’s how wealth gets built in biotech—not through sure things (they don’t exist), but through situations where you’ve carefully assessed the risk and found the payoff compelling.
The Monkey Momentum Perspective
Rocket’s momentum has clearly been disrupted. The +42.8% in 20 days that Foxy noted appears to have reversed significantly. But disrupted momentum in the presence of positive catalysts is sometimes the best entry point. It’s the moment when the smart money is starting to buy what the panicked money is selling.
The low beta (0.574) means this won’t keep pace with a bull market, but it also means it won’t crater 50% in a market correction. That’s insurance. And insurance is underrated when you’re sitting in a risky asset.
My only real hesitation is the same one I have with all biotech: too much depends on clinical trial results you cannot predict. But Rocket has now crossed one major milestone. They have FDA approval. They have proof of concept. They have a validation that their approach works. That’s worth something, and the market has priced it at roughly nothing.
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys – no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
COMING NEXT WEEK: Maurice investigates whether quantum computing companies are actually quantum computing or just really good at throwing shade at classical computers.
Maurice’s Final Wisdom: “The market hates uncertainty until it doesn’t. The trick is catching the moment when certainty starts to emerge. Rocket just got certainty. The market is still processing it.”
Trained Market Monkey 